C110-19 Association of Pre-treatment Interstitial Lung Abnormalities in Patients With Locally Advanced Non-smell Lung Cancer With Risk for Immune Checkpoint Inhibitor Pneumonitis
Rattachement africain : us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Abstract Rationale Patients with locally advanced non-small cell lung cancer (NSCLC) treated with concurrent chemoradiation (CRT) and immune checkpoint inhibitors (ICI) are at high risk for developing ICI pneumonitis (ICI-P). Prior studies suggest that pre-treatment interstitial lung abnormalities (ILAs) increase the risk for ICI-P, but these studies have not focused on locally advanced NSCLC treated with CRT-ICI. We sought to determine whether pre-treatment ILA patterns increase the risk for ICI-P in locally advanced NSCLC treated with CRT-ICI. Methods Baseline chest CT scans from 97 patients enrolled in the Gateway project were retrospectively reviewed. Inclusion criteria required standard of care CRT followed by three months minimum of ICI therapy. ILAs were classified based on Fleischner Society criteria into: no ILA, any ILA, subpleural ILA, and subpleural fibrotic (SF) ILA. Measured ILAs included ground-glass opacities (GGO), reticular opacities, honeycombing, traction bronchiectasis, and architectural distortion. ILAs were coded as present or absent and ICI-P development was defined as a binary outcome. Univariable logistic regression models were used to evaluate associations between ILAs and pneumonitis. Results The incidence of ICI pneumonitis in our cohort was 28%. There was no significant association between age or sex and ICI-P. SF ILAs showed a borderline association with ICI-P (OR 3.0; 95% CI: 0.88-10.0). ILAs most associated with ICI-P were GGOs (OR 3.3; 95% CI: 1.22-8.9) and traction bronchiectasis (OR 9.4; 95% CI: 1.9-47). Subpleural GGOs showed a similar association to ICI-P as any GGOs (OR 3.4; 95% CI: 1.1-10.6). Conclusions Pre-treatment traction bronchiectasis appears to be the strongest predictor of ICI-related pneumonitis, supporting previous studies showing the association of traction bronchiectasis with progression from ILA to interstitial lung disease. Study limitations include small sample size, lack of multiple testing correction, and possible underestimation of ICI-P due to censoring from disease progression. Future analyses incorporating competing risk models and quantitative ILA scores are underway. This abstract is funded by: None
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- C110-19 Association of Pre-treatment Interstitial Lung Abnormalities in Patients With Locally Advanced Non-smell Lung Cancer With Risk for Immune Checkpoint Inhibitor Pneumonitis
- Date Crossref
- 01/05/2026
- Éditeur
- Oxford University Press (OUP)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
The University of Texas Health Science Center pays non établi dans la noticeUniversité ou école supérieure
-
Baylor College of Medicine pays non établi dans la noticeUniversité ou école supérieure
-
The University of Texas MD Anderson Cancer Center pays non établi dans la noticeÉtablissement de santé
-
Johns Hopkins University pays non établi dans la noticeUniversité ou école supérieure
-
Johns Hopkins Medicine pays non établi dans la noticeÉtablissement de santé
-
Columbus State Community College pays non établi dans la noticeUniversité ou école supérieure
-
State Library of Ohio pays non établi dans la noticeInstitution
-
The Ohio State University pays non établi dans la noticeUniversité ou école supérieure
-
McGovern Medical School UTHealth pays non établi dans la noticeInstitution
-
University of Houston McGovern Medical School pays non établi dans la noticeUniversité ou école supérieure
-
The Univ of Texas At MD Anderson Cancer Center pays non établi dans la noticeUniversité ou école supérieure
The University of Texas Health Science Center, Baylor College of Medicine et The University of Texas MD Anderson Cancer Center, avec 8 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.